{"organizations": [], "uuid": "d45e569c559ea44e7f158fed3c3d6146b147c42d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-merck-announces-discontinuation-of/brief-merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-for-the-treatment-of-people-with-prodromal-alzheimers-disease-idUSFWN1Q31H7", "country": "US", "domain_rank": 408, "title": "Merck Announces Discontinuation Of APECS Study Evaluating Verubecestat For The Treatment Of People With Prodromal Alzheimer’S Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-02-14T05:39:00.000+02:00", "replies_count": 0, "uuid": "d45e569c559ea44e7f158fed3c3d6146b147c42d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-merck-announces-discontinuation-of/brief-merck-announces-discontinuation-of-apecs-study-evaluating-verubecestat-for-the-treatment-of-people-with-prodromal-alzheimers-disease-idUSFWN1Q31H7", "ord_in_thread": 0, "title": "Merck Announces Discontinuation Of APECS Study Evaluating Verubecestat For The Treatment Of People With Prodromal Alzheimer’S Disease", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "merck", "sentiment": "negative"}, {"name": "reuters) - merck & co inc", "sentiment": "neutral"}, {"name": "merck & co inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Merck & Co Inc:\n* MERCK ANNOUNCES DISCONTINUATION OF APECS STUDY EVALUATING VERUBECESTAT (MK-8931) FOR THE TREATMENT OF PEOPLE WITH PRODROMAL ALZHEIMER’S DISEASE\n* MERCK & CO INC - ‍EDMC CONCLUDED THAT IT WAS UNLIKELY THAT POSITIVE BENEFIT/RISK COULD BE ESTABLISHED IF TRIAL CONTINUED​\n* MERCK & CO INC - ‍DECISION TO STOP STUDY FOLLOWS A RECOMMENDATION BY EXTERNAL DATA MONITORING COMMITTEE​\n* MERCK & CO INC - ‍IT WILL BE STOPPING PROTOCOL 019, ALSO KNOWN AS APECS STUDY​\n* MERCK & CO INC - ‍STOPPING PROTOCOL 019, ALSO KNOWN AS APECS STUDY, A PHASE 3 STUDY EVALUATING VERUBECESTAT (MK-8931)​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T05:39:00.000+02:00", "crawled": "2018-02-14T12:48:54.013+02:00", "highlightTitle": ""}